Table 1.
Patient, donor and transplant characteristics (N=134)
| Characteristic | Value |
|---|---|
| Age at transplant, median (range), years | 44 (15–73) |
| Patient gender, male, n (%) | 83 (62) |
| Disease, n (%) | |
| AML and MDS | 60 (44.8) |
| - CR1/CR2 | 42 |
| - > CR2 | 18 |
| B and T-ALL | 22 (16.4) |
| - CR1/CR2 | 18 |
| - > CR2 | 4 |
| “Other” diagnoses included | |
| HL | 9 (6.7) |
| - CR1/CR2 | 3 |
| - > CR2 | 6 |
| MM | 8 (6.0) |
| - CR | 3 |
| - PR/VGPR | 5 |
| CML | 6 (4.5) |
| - 2nd CP | 2 |
| - AP | 3 |
| - BP | 1 |
| NHLa | 17 (12.7) |
| - CR1/CR2 | 10 |
| - > CR2 | 7 |
| CLL | 4 (3.0) |
| - CR1/CR2 | 1 |
| - > CR2 | 3 |
| Therapy related myeloid neoplasm | 3 (2.2) |
| - PR | 2 |
| - Active disease | 1 |
| CMML | 3 (2.3) |
| - Active disease | 3 |
| MPN (myelofibrosis) | 1 (0.8) |
| - Active disease | 1 |
| Blastic plasmacytoid dendritic cell tumor | 1 (0.8) |
| - CR1 | 1 |
| EBMT risk score | |
| 1–2 | 27 (20.1) |
| 2–4 | 63 (47.0) |
| >= 5 | 44 (32.8) |
| Conditioning | |
| - MAC-busulphan based | 46 (34.3) |
| - MAC-TBI based | 31 (23.1) |
| - RIC-TBI based | 57 (42.6) |
| Donor age, median (range), y | 36 (9–68) |
| Donor gender, male, n (%) | 78 (58) |
| Donor to recipient gender mismatch | |
| - Female to male | 31 (23.1) |
| - Male to female | 26 (19.4) |
| - Matched | 77 (57.5) |
| Stem cell source | |
| - PBSC | 95 (70.9) |
| - BM | 36 (26.9) |
| - PBSC and BM | 3 (2.2) |
| Recipient/donor CMV serostatus | |
| - Neg/neg | 7 (5.2) |
| - Neg/pos | 9 (6.7) |
| - Pos/neg | 7 (5.2) |
| - Pos/pos | 77 (57.5) |
| - Missing | 34 (25.4) |
| Donor relationship | |
| - Son | 46 (34.3) |
| - Mother | 25 (18.7) |
| - Brother | 24 (17.9) |
| - Sister | 17 (12.7) |
| - Daughter | 14 (10.5) |
| - Father | 5 (3.7) |
| - Other family member male/female | 3 (2.3) |
| Number of previous transplants | |
| - 0 | 110 (82.1) |
| - 1 | 19 (14.2) |
| - 2 | 5 (3.7) |
| Centre | |
| - Groote Schuur hospital | 24 (17.9) |
| - Pretoria East Netcare | 110 (82.1) |
| Acute GVHD | |
| - Yes | 45 (41.7) |
| - No | 63 (58.3) |
| Acute GVHD grade | |
| - I | 17 (37.8) |
| - II | 19 (42.2) |
| - III | 6 (13.3) |
| - IV | 3 (6.7) |
Abbreviations: AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukaemia; HL, Hodgkin lymphoma; MM, multiple myeloma; CML, chronic myeloid leukaemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukaemia; CMML, chronic myelomonocytic leukaemia; MPN, myeloproliferative neoplasm; PBSC, peripheral blood stem cells; BM, bone marrow; CMV, cytomegalovirus; CR, complete remission; PR, partial remission; VGPR, very good partial response; CP, chronic phase; AP, accelerated phase; BP, blastic phase; MAC, myeloablative chemotherapy; RIC, reduced intensity conditioning; TBI, total body irradiation
NHL includes high grade B cell, low grade B cell and T cell not otherwise specified.